Consort Medical plc (CSRT) Receives Consensus Rating of “Buy” from Brokerages
Shares of Consort Medical plc (LON:CSRT) have been given a consensus recommendation of “Buy” by the seven brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,178.17 ($15.78).
Separately, Stifel Nicolaus reissued a “buy” rating and set a GBX 1,250 ($16.74) price objective on shares of Consort Medical in a research report on Thursday, November 9th.
Consort Medical (LON CSRT) opened at GBX 1,158 ($15.51) on Monday. Consort Medical has a fifty-two week low of GBX 960 ($12.86) and a fifty-two week high of GBX 1,170 ($15.67).
Consort Medical Company Profile
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.